The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of combined biomarkers for tumor response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC).
 
Hayat Oum El Kheir Ramdani
No Relationships to Disclose
 
Markus Falk
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Pfizer
 
Stefanie Schatz
No Relationships to Disclose
 
Markus Tiemann
Honoraria - AstraZeneca; BMS Brazil; Boehringer Ingelheim; MSD; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Novartis (Inst)
 
Lukas Heukamp
Employment - Hämatopathologie Hamburg; NEO New Oncology
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche Pharma AG
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Roche Pharma AG
 
Ed Schuuring
Honoraria - Abbott; Agena Bioscience; Agena Bioscience; AstraZeneca; Bayer; Bayer; Bio-Rad; Bio-Rad; Biocartis; Biocartis; Bristol-Myers Squibb; Bristol-Myers Squibb; Illumina; Illumina; Janssen-Cilag; Janssen-Cilag; Novartis; Novartis; Pfizer; Pfizer; Roche; Roche
Consulting or Advisory Role - Abbott; Abbott; Agena Bioscience; Agena Bioscience; AstraZeneca; AstraZeneca; Bayer; Bayer; Bio-Rad; Bio-Rad; Biocartis; Biocartis; Bristol-Myers Squibb; Bristol-Myers Squibb; Illumina; Illumina; Janssen-Cilag; Janssen-Cilag; Novartis; Novartis; Pfizer; Pfizer; Roche; Roche
Research Funding - Bio-Rad (Inst); Bio-Rad (Inst); Biocartis (Inst); Biocartis (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Cancer-ID (Inst); Cancer-ID (Inst); Roche (Inst); Roche (Inst)
 
Harry J.M. Groen
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Lilly (Inst); Roche (Inst)
 
Frank Griesinger
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)